Journals / Bezmiâlem Science / 2016 / Cilt: 4 - Sayı: 1

Radioembolization Treatment for Liver Cancer

Karaciğer Tümörlerinde Radyoembolizasyon Tedavisi

Pages
25–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is hoped that the effectiveness of radioembolization is further increased in the future by technological developments, researches on dosimetry, its use along with radiosensitizing agents, and various treatment combinations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although curative treatment is surgery (resection/transplantation) and for small lesions ablative strategies, in primary liver carcinomas such as hepatocellular carcinoma and cholangiocellular carcinoma, palliative treatment is used for most of these patients because of lack of surgical options.
📊
Key Findings & Data:In recent years, transarterial radioembolization with yttrium-90 microsphere has emerged as a local treatment option in primary and metastatic liver tumors.
💡
Conclusion & Impact:It is hoped that the effectiveness of radioembolization is further increased in the future by technological developments, researches on dosimetry, its use along with radiosensitizing agents, and various treatment combinations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although curative treatment is surgery (resection/transplantation) and for small lesions ablative strategies, in primary liver carcinomas such as hepatocellular carcinoma and cholangiocellular carcinoma, palliative treatment is used for most of these patients because of lack of surgical options. These treatments are regional treatments such as transarterial chemoembolization, radiofrequency ablation, or microwave ablation and systemic treatments such as tyrosine kinase inhibitors. Surgery and chemotherapy are the main treatment options for metastatic liver tumors, particularly in colorectal tumors, although local treatment options are used for these patients. In recent years, transarterial radioembolization with yttrium-90 microsphere has emerged as a local treatment option in primary and metastatic liver tumors. The aim of this treatment is to provide an effective radiation dose distribution for the tumor in the liver tissue and to give the lowest dose in order to not harm the intact liver tissue. Radioembolization has proven to be as effective as other available palliative treatments in primary and secondary liver tumors and is a treatment method that is well tolerated. It has a risk for serious life-threatening complications, although this rate is low. Toxicity can be kept at a minimum with adequate technical and rigorous application in experienced hands and in accordance with multidisciplinarity. It is hoped that the effectiveness of radioembolization is further increased in the future by technological developments, researches on dosimetry, its use along with radiosensitizing agents, and various treatment combinations.

Özet

Hepatoselüler karsinom ve kolanjioselüler karsinom gibi primer karaciğer kanserlerinde öncelikli olarak küratif tedaviler (rezeksiyon, transplantasyon ve küçük lezyonlar için ablasyon yöntemleri) düşünülmekle birlikte bu hastaların çoğu tanı anında cerrahi şansına sahip olamadığından dolayı palyatif tedavi seçenekleri söz konusu olmaktadır. Bunlar transarteriyal kemoembolizasyon (TAKE), radyofrekans ablasyon (RF) ya da mikrodalga ablasyon gibi lokal tedaviler ile tirozin kinaz inhibitörleri gibi sistemik tedavilerdir. Kolorektal tümörler başta olmak üzere metastatik karaciğer tümörlerinde başlıca tedavi seçenekleri ise cerrahi ve kemoterapi olmakla birlikte lokal tedavi seçenekleri de uygulanmaktadır. Son yıllarda primer ve metastatik karaciğer tümörlerinin lokal tedavi seçenekleri arasında Yttrium-90 (Y-90) yüklü mikroküreler ile yapılan transarteriyal radyoembolizasyon yer almaktadır. Bu tedavinin amacı karaciğer içindeki tümörlü dokulara etkin bir radyasyon dozu dağılımını sağlamak ve bunu yaparken sağlam karaciğer dokusuna zararlı olmayan, en az dozu vermektir. Radyoembolizasyonun primer ve sekonder karaciğer tümörlerinde mevcut diğer palyatif tedaviler kadar etkin olduğu kanıtlanmış olup iyi tolere edilen bir tedavi yöntemidir. Komplikasyon oranları düşük olmakla birlikte yaşamı tehdit etme potansiyeli olan ciddi komplikasyonları da vardır. Deneyimli ellerde ve multidisipliner uyum içerisinde, yeterli teknik ve titiz bir uygulama ile toksisite minimumda tutulabilmektedir. Gelecekte teknolojik gelişmeler ile dozimetri konusundaki çalışmaların, radyosensitize eden ajanlar ile birlikte kullanımının ve çeşitli tedavi kombinasyonlarının radyoembolizasyonun etkinliğini daha da arttırması ümit edilmektedir.

🔖

Cite This Article

ERDOĞAN, E. B., ÖZDEMİR, H. M., AYDIN, M. (2016). Radioembolization Treatment for Liver Cancer. Bezmiâlem Science, Cilt: 4 - Sayı: 1, 25–32. https://ajindex.com/articles/352586

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-10. [CrossRef] 2. Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7: 406-24. [CrossRef] 3. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5. [CrossRef] 4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90. [CrossRef] 5. Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology 2013; 266: 407-30. [CrossRef] 6. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31: 1237-48. [CrossRef] 7. McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 1998; 16: 2246-52. 8. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, et al. PhaseII trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23: 8739-47. [CrossRef] 9. Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006; 66: 1152-8. [CrossRef] 10. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995; 33: 919-24. [CrossRef] 11. Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63: 672-82. [CrossRef]